Adding Value to US Pipelines Through Asian Assets & Fast-Tracking US Innovation Through Efficiency in China
Time: 2:30 pm
day: Day Two - PM
Details:
- Discussing deals with Asia to date, their characteristics, and the change in momentum
- Highlighting the benefits of US phase 1 trials of Asian assets to overcome the challenge of underreporting of patient reported toxicity and leveraging efficiency in China to fast-track US innovation through clinical studies
- Reviewing increasing US ADC portfolios more cost-effectively through phase 1 Asian assets